Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: Five-year posttrial follow- up report from the POSCH

Archives of Internal Medicine

Volumn 158, Issue 11, 1998, Pages 1253-1261

  Buchwald, Henry ^a   Varco, Richard L ^a   Boen, James R ^a   Williams, Stanley E ^a   Hansen, Betty J ^a   Campos, Christian T ^a   Campbell, Gilbert S ^a   Pearce, Malcolm B ^a   Yellin, Albert E ^a   Allan Edmiston, W ^a   Smink Jr , Robert D ^a   Sawin Jr , Henry S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERLIPIDEMIA; ILEUM BYPASS; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; JEJUNOILEAL BYPASS; LIPIDS; MALE; MIDDLE AGED; MORBIDITY; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 7144250513     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.11.1253     Document Type: Article

References (68)

1. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
2. Buchwald H, Matts JP, Fitch LL, et al. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA. 1992;268:1429-1433.
3. Campos CT, Buchwald H. Lipid lowering and regression of atherosclerosis: partial ileal bypass surgery. Controversies Card. 1993;4:9-12.
4. Buchwald H, Fitch LL, Matts JP, Hansen BJ, Stuenkel MR, and the POSCH Group. Perception of quality of life before and after disclosure of a trial's results: a report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). Control Clin Trials. 1993;14:500-510.
5. Fitch LL, Buchwald H, Matts JP, Johnson JW, Campos CT, Long JM, for the POSCH group. Effect of aspirin use on death and recurrent myocardial infarction in current and former cigarette smokers. Am Heart J. 1995;129:656-662.
6. Matts JP, Buchwald H, Fitch LL, et al. Subgroup analyses of the major clinical endpoints in the Program on the Surgical Control of the Hyperlipidemias (POSCH): overall mortality, atherosclerotic coronary heart disease (ACHD) mortality, and ACHO mortality or myocardial infarction. J Clin Epidemiol. 1995;48:389-405.
7. Buchwald H, Campos CT, Boen JR, Nguyen PA, Williams SE, and the POSCH Group. Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). J Am Coll Cardiol. 1995;26:351-357.
8. Campos CT, Nguyen P, Buchwald H, and the POSCH Group. Effective cholesterol lowering reduces the incidence of and improves the survival following coronary revascularization: POSCH long-term follow-up study. Circulation. 1996;93:632.
9. Buchwald H, Bourdages HR, Campos CT, Nguyen P, Williams SE, Boen JR, for the POSCH Group. Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH). Surgery. 1996;120:672-679.
10. Buchwald H, Campos CT, Boen JR, Nguyen P, et al. Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials. Ann Surg. 1996;224:486-500.
11. Buchwald H, Matts JP, Fitch LL, et al. Program on Surgical Control of the Hyperlipidemias (POSCH): design and methodology. J Clin Epidemiol. 1989;42:1111-1127.
12. Buchwald H. Lowering of cholesterol absorption and blood levels by ileal exclusion: experimental basis and preliminary clinical report. Circulation. 1964;29:713-720.
13. Buchwald H, Moore RB, Varco RL. Surgical treatment of hyperlipidemia. Circuiation. 1974;49(suppl):I-1-I-37.
14. Buchwald H. Intestinal bypass for hypercholesterolemia. In: Nyhus LM, Baker RJ, eds. Mastery of Surgery. Boston, Mass: Little Brown & Co Inc; 1981;3:901-907.
15. Buchwald H, Campos CT. Partial ileal bypass for control of hyperlipidemia and atherosclerosis. In: Sabiston DC Jr, Spencer FC, eds. Surgery of the Chest. 5th ed. Philadelphia, Pa: WB Saunders Co; 1990:1799-1819.
16. Koivisto P, Miettinen TA. Long-term effects of ileal bypass on lipoproteins in patients with familial hypercholesterolemia. Circulation. 1984;70:290-296.
17. Schouten JA, Beynen AC. Partial ileal bypass in the treatment of heterozygous familial hypercholesterolemia: a review. Artery. 1986;13:240-263.
18. Sandler H, Dodge HT. The use of single plane angiocardiograms for the calculation of the left ventricular volume in man. Am Heart J. 1968;75:325-334.
19. National Heart and Lung Institute, Lipid Research Clinics Program. Manual of Laboratory Operations. Bethesda, Md: National Institutes of Health; 1974. US Dept of Health, Education, and Welfare publication NIH 75-628.
20. Hatch FT, Lees RS. Practical methods for plasma lipoprotein analysis. Adv Lipid Res. 1968;6:1-68.
21. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull World Health Organ. 1970;43:891-915.
22. Buchwald H, Matts JP, Hansen BJ, Long JM, Fitch LL, for the POSCH Group. Program on Surgical Control of the Hyperlipidemias (POSCH): recruitment experience. Control Clin Trials. 1987;8(suppl 4):94S-104S.
23. Lee ET. Statistical Methods for Survival Data Analysis. Belmont, Calif: Lifetime Learning Publishing; 1980.
24. Cox DR. Regression models and life-tables. J R Stat Soc (B). 1972;34:1887-1220.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
26. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
27. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly censored samples. Biometrika, 1965;52:203-223.
28. Matts JP, Buchwald H, Fitch LL, et al. Program on the Surgical Control of the Hyperlipidemias (POSCH): patient entry characteristics. Control Clin Trials. 1991;12:314-339.
29. Campos CT, Matts JP, Fitch LL, Speech JC, Long JM, Buchwald HB, and the POSCH Group. Lipoprotein modification achieved by partial ileal bypass: five-year results of the POSCH trial. Surgery. 1987;102:424-432.
30. Campos CT, Matts JP, Fitch LL, Speech JC, Long JM, Buchwald HB, and the POSCH Group. Normalization of lipoproteins following partial ileal bypass in individual WHO lipoprotein phenotypes. Curr Surg. 1988;45:380-382.
31. Campos CT, Matts JP, Fitch LL, Speech J, Long JM, Buchwald H, for the POSCH Group. Comparisons of lipoprotein results in men and women after partial ileal bypass for hypercholesterolemia. Surg Forum. 1988;39:193-195.
32. Campos CT, Matts JP, Santilli SM, et al. Predictors of total and LDL cholesterol change following partial ileal bypass. Am J Surg. 1988;155:138-146.
33. Rayer PFO. Traité théorique et pratique des maladies de la peau. Paris, France: JB Ballillière; 1835.
34. Addison T, Gull W. On a certain affection of the skin, vitiligoidea: a. plana, b. tuberosa. Guys Hosp Rep. 1851;7:267-277.
35. Ignatovski Al. Zur Frage über den Einfluss der animalischen Nahrung auf den Kaninchenorganismus. Izviest Imp Voyenno Med Akad S Petersb. 1908;16:154-176.
36. Anitschkow N, Chalatow S. Lieber experimentelle Cholesterinsteatose und ihre Bedeutung für die Entstehung einiger pathologischer Prozesse. Cent Allg Pathol Anat. 1913;24:1-9.
37. Wacker L, Hueck W. Ueber experimentelle Atherosklerose und Cholesterinemie. Münchener Med Wochenschr. 1913;60:2097-2100.
38. Keys A, Aravanis C, Blackburn H, et al. Coronary heart disease in seven countries. Circulation. 1970;41(suppl):I-1-I-211.
39. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham Study. Ann Intern Med. 1971;74:1-12.
40. The Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and EGG abnormalities to the incidence of major coronary events: final report of the Pooling Project J Chronic Dis. 1978;31:201-306.
41. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
42. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256:2835-2838.
43. Ragland DR, Brand RJ. Coronary heart disease mortality in the Western Collaborative Group Study: follow-up experience of 22 years. Am J Epidemiol. 1988;127:462-475.
44. Katz LN, Stamler J, Pick R. Nutrition and Atherosclerosis. Philadelphia, Pa: Lea & Febiger; 1958.
45. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
46. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
47. Buchwald H, Fitch L, Moore RB. Overview of randomized clinical trials of lipid intervention for atherosclerotic cardiovascular disease. Control Clin Trials. 1982;3:271-283.
48. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
49. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
50. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with chylostyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:313-324.
51. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in the incidence of coronary heart disease. JAMA. 1984;251:351-364.
52. Brown G, Alpers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
53. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesteroiemia with combined drug regimens. JAMA. 1990;264:3007-3012.
54. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-569.
55. Gould KL, Ornish D, Kirkeeide R, et al. Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. Am J Cardiol. 1992;69:845-853.
56. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
57. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction in coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
58. MAAS Investigators. Effect of simvastatin on coronary atheroma: a Multicentre Antiatheroma Study. Lancet. 1994;344:633-638.
59. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
60. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
61. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
62. Sheperd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesteroiemia. N Engl J Med. 1995;333:1301-1307.
63. Sacks FM, Rouleau JL, Moye LA, et al. Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. Am J Cardiol. 1995;75:621-623.
64. The LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-Term Intervention With Pravastatin in Ischemic Disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol. 1995;76:474-479.
65. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
66. The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA. 1990;263:1795-1801.
67. The Lipid Research Clinics Investigators. The Lipid Research Clinics: Coronary Primary Prevention Trial. Arch Intern Med. 1992;152:1399-1410.
68. Heinonen OP, Huttunen JK, Manninen V, et al. The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up. J Intern Med. 1994;235:41-49.